Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy

被引:30
|
作者
Noordhof, A. L. [1 ]
Damhuis, R. A. M. [2 ]
Hendriks, L. E. L. [3 ]
de Langen, A. J. [4 ]
Timens, W. [5 ]
Venmans, B. J. W. [1 ]
van Geffen, W. H. [1 ]
机构
[1] Med Ctr Leeuwarden, Dept Resp Med, Henri Dunantweg 2, NL-8934 AD Leeuwarden, Netherlands
[2] Comprehens Canc Org, Dept Res, Plesmanlaan 121, NL-1066 CX Utrecht, Netherlands
[3] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Resp Med, Med Ctr, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands
[4] Netherlands Canc Inst, Dept Thorac Oncol, NL-1007 MB Amsterdam, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands
关键词
Non-small cell lung cancer; Kirsten rat sarcoma; Mono-immunotherapy; PREDICTIVE-VALUE; CANCER; EFFICACY; INHIBITORS; DOCETAXEL; SURVIVAL; THERAPY;
D O I
10.1016/j.lungcan.2021.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Monotherapy with pembrolizumab is the preferred first-line treatment for metastatic non-small cell lung cancer with programmed death-ligand 1 (PD-L1) expression 50 %, without targetable oncogenic drivers. Although targeted therapies are in development for patients with specific Kirsten rat sarcoma (KRAS) mutations, these are not available in daily care yet. It is not clear whether there is a difference in survival on first-line pembrolizumab for patients with a high PD-L1 status with or without a KRAS mutation. We aim to compare this survival based on real-world data. Materials and methods: This is a real-world retrospective population-based study using data from the Netherlands Cancer Registry. We selected patients with stage IV lung adenocarcinoma with PD-L1 expression >50 % diagnosed between January 2017 and December 2018, treated with first-line pembrolizumab. Patients with EGFR mutations, ALK translocations or ROS1 rearrangements were excluded. The primary outcome parameter was overall survival. Results: 388 (57 %) of 595 patients had a KRAS mutation. KRAS was seen more frequently in women than in men (65 % versus 49 % respectively, p < 0.001). The median overall survival was 19.2 months versus 16.8 months for patients with and without KRAS mutation, respectively (p = 0.86). Multivariable analysis revealed WHO performance score, number of organs with metastases and PD-L1 percentage as independent prognostic factors. KRAS mutation status had no prognostic influence (hazard ratio = 1.03, 95 % CI 0.83-1.29). Conclusion: The survival of KRAS mutated versus KRAS wild-type lung adenocarcinoma patients, treated with first-line pembrolizumab monotherapy, is similar, suggesting that KRAS has no prognostic value with respect to treatment with pembrolizumab.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 50 条
  • [31] Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy
    Herranz-Bayo, Elena
    Chara-Velarde, Luis Enrique
    Cassinello-Espinosa, Javier
    Gimeno-Ballester, Vicente
    Artal-Cortes, Angel
    Moratiel-Pellitero, Alba
    Alcacera-Lopez, Arancha
    Navarro-Exposito, Fatima
    Riesco-Montes, Blanca
    Clemente-Andujar, Manuel
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 1484 - 1492
  • [32] The Prognostic Value of Metastasis to Different Organs in EGFR-Mutated Stage IV NSCLC Patients Treated with First-Line Icotinib
    Wang, Y.
    Wang, L.
    Zuo, J.
    Feng, L.
    Fan, Z.
    Zhang, X.
    Han, J.
    Zhou, X.
    Li, B.
    Su, N.
    Du, H.
    Zhou, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S420 - S421
  • [33] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
  • [34] Prognostic Implications of KRAS Mutation Status and KRAS Mutation Type in Patients With Advanced NSCLC Treated With Cytotoxic Chemotherapy
    Iams, W. T.
    Hames, M. L.
    Chen, H.
    Aston, J. L.
    Horn, L.
    Lovly, C. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S42 - S42
  • [35] Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study
    Trestini, Ilaria
    Belluomini, Lorenzo
    Dodi, Alessandra
    Sposito, Marco
    Caldart, Alberto
    Kadrija, Dzenete
    Pasqualin, Luca
    Riva, Silvia Teresa
    Scaglione, Ilaria Mariangela
    Tregnago, Daniela
    Avancini, Alice
    Insolda, Jessica
    Confortini, Linda
    Casali, Miriam
    Menis, Jessica
    Vita, Emanuele
    Cintoni, Marco
    Todesco, Marco
    Milanese, Gianluca
    Sperduti, Isabella
    D'Onofrio, Mirko
    Infante, Marco
    Tiseo, Marcello
    Mele, Maria Cristina
    Tortora, Giampaolo
    Milella, Michele
    Bria, Emilio
    Pilotto, Sara
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2024, 15 (06) : 2349 - 2360
  • [36] HER-2 Mutation Is Not a Prognostic Factor Treated with First-Line Chemotherapy in NSCLC Patients
    Zhao, C.
    Li, X.
    Jiang, T.
    Su, C.
    Chen, X.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1967 - S1967
  • [37] FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN
    Yang, Chih Jen
    Tsai, Ming-Ju
    Hung, Jen-Yu
    Lee, Mei-Hsuan
    Huang, Ming-Shyan
    Chong, Inn-Wen
    RESPIROLOGY, 2018, 23 : 293 - 293
  • [38] KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
    Rita Chiari
    Silvia Palladino
    Rita Emili
    Mariagrazia De Lisa
    Donatella Sarti
    Vincenzo Catalano
    Mauro Magnani
    Francesco Graziano
    Annamaria Ruzzo
    Scientific Reports, 13
  • [39] KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
    Chiari, Rita
    Palladino, Silvia
    Emili, Rita
    De Lisa, Mariagrazia
    Sarti, Donatella
    Catalano, Vincenzo
    Magnani, Mauro
    Graziano, Francesco
    Ruzzo, Annamaria
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [40] The Effectiveness of Local Consolidative Therapy for Advanced Lung Adenocarcinoma Harboring EGFR Mutation Treated With First-line Afatinib
    Tsai, Y.
    Tsai, M.
    Ma, J.
    Kuo, C.
    Yang, C.
    Wu, K.
    Lee, M.
    Lee, Y.
    Huang, C.
    Hung, J.
    Chong, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207